Rezolute, Inc.
Processes for preparing plasma kallikrein inhibitors

Abstract:

A process for preparing and purifying a compound of Formula I is provided: ##STR00001## or a salt thereof, wherein the subscript m is an integer of from 0 to 3; each R.sup.a is independently selected from the group consisting of (C.sub.3-C.sub.8)cycloalkyl, (C.sub.1-C.sub.4)haloalkyl, halogen, --OH, --OR.sup.1, --SH, --SR.sup.1, --S(O)R.sup.1, --S(O).sub.2R.sup.1, --SO.sub.2NH.sub.2, --C(O)NH.sub.2, --C(O)NHR.sup.1, --C(O)N(R.sup.1).sub.2, --C(O)R.sup.1, --C(O)H, --CO.sub.2R.sup.1, --NO.sub.2, --NH.sub.2, --NHR.sup.1, --N(R.sup.1).sub.2, wherein each R.sup.1 is independently (C.sub.1-C.sub.8)alkyl; L is a linking group selected from the group consisting of a bond or CH.sub.2; Q.sup.a, Q.sup.b, and Q.sup.c are each members independently selected from the group consisting of N, S, O and C(R.sup.q) wherein each R.sup.q is independently selected from the group consisting of H, C.sub.1-8 alkyl, halo and phenyl, and the ring having Q.sup.a, Q.sup.b, Q.sup.c and Y as ring vertices is a five-membered ring having two double bonds; and Y is selected from the group consisting of C and N.